文献速递心脑血管急症重症综合管理与镇静镇痛

院外心脏骤停患者中期(30至90天)神经功能变化:一项全国性回顾性研究(JAAM-OHCA登记研究)

Mid-term (30- to 90-day) neurological changes in out-of-hospital cardiac arrest patients: A nationwide retrospective study (the JAAM-OHCA registry).
PubMed 文献 · Am J Emerg Med · 2022-05-19
一句话结论日本全国登记显示院外心脏骤停幸存者30至90天仅7%神经功能改善、14%恶化,目标温度管理是与改善独立相关的因素(aOR 1.69)。

该研究基于日本全国院外心脏骤停(OHCA)登记数据(2014年6月至2017年12月)进行回顾性分析,纳入年龄≥18岁、30天内未死亡且30天和90天脑功能分级(CPC)评分完整的OHCA患者1868例。90天时CPC 1分866例(46%)、CPC 2分154例(8.2%)、CPC 3分224例(12%)、CPC 4分392例(20%),30至90天期间死亡232例(CPC 5,12%)。30至90天CPC改善133例(7%),恶化260例(14%);多因素logistic回归显示目标温度管理是30至90天神经功能改善的独立因素(校正OR 1.69,95%CI 1.07-2.68)。提示院外心脏骤停幸存者中期神经功能以稳定或恶化为多,目标温度管理可能与中期改善相关。

要点

  • 1868例院外心脏骤停幸存者中,30至90天CPC改善仅133例(7%),恶化260例(14%),死亡232例(12%)。
  • 90天时CPC 1分866例(46%)、CPC 2分154例(8.2%)、CPC 3分224例(12%)、CPC 4分392例(20%)。
  • 目标温度管理是30至90天神经功能改善的独立因素(校正OR 1.69,95%CI 1.07-2.68)。
  • 改善者中多数为CPC评分从2分改善至1分。

适用人群与场景

  • 日本全国OHCA登记中年龄≥18岁的院外心脏骤停患者。
  • 排除30天内死亡者以及30天和90天CPC评分缺失者。

诊断标准与关键阈值

  • 神经功能采用脑功能分级(CPC)评分评估,CPC 1分和2分为良好神经结局。

研究设计与关键结果

  • 研究类型:基于日本全国OHCA登记的回顾性研究,数据收集时间为2014年6月至2017年12月。
  • 登记共34,745例患者,最终分析1868例。
  • 90天时良好神经结局(CPC 1分和2分)1020/1868例;CPC 1分866例(46%)、CPC 2分154例(8.2%)、CPC 3分224例(12%)、CPC 4分392例(20%)。
  • 30至90天期间死亡232例(CPC 5,12%)。
  • 30至90天CPC评分改善133例(7%),恶化260例(14%);改善者中多数为CPC评分从2分改善至1分。
  • 目标温度管理是30至90天神经功能改善的独立因素(校正OR 1.69,95%CI 1.07-2.68)。

证据类型、等级与局限

  • 证据类型:基于全国登记数据的回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,目标温度管理与院外心脏骤停患者30至90天CPC评分改善独立相关(校正OR 1.69,95%CI 1.07-2.68)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Few studies have focused on mid/long-term neurological changes in out-of- hospital cardiac arrest (OHCA) survivors. Some studies suggest that there is still a slow, small, progressive improvement in cognitive function and quality of life for this population, even in the mid/long term. However, clinical data focused on mid/long-term outcomes for OHCA patients are still lacking. This study aimed to assess mid-term neurological changes in OHCA patients. We summarized patients' improved or worsened neurological changes between 30 and 90 days. Then we identified the relationship between clinical variables and 30- to 90-day neurological improvement.

METHODS: A retrospective review of data (Jun 2014 - Dec 2017) from a Japanese nationwide OHCA registry was conducted. Inclusion criteria were OHCA patients ≥18 years old. Exclusion criteria were death within 30 days and missing Cerebral Performance Category (CPC) score at 30 and 90 days. We described the distributions of 30-day and 90-day CPC scores as well as the number and portion of patients whose CPC scores improved and worsened between 30 and 90 days. Additionally, factors affecting improved neurological changes over the time period were examined using multivariable logistic regression.

RESULTS: Of the registry's 34,745 patients, 1868 were analyzed. Favorable neurological outcomes (CPC scores of 1 and 2) were seen in 1020/1868 patients at 90 days. CPC scores at 90 days were: CPC 1: 866 (46%), CPC 2: 154 (8.2%), CPC 3: 224 (12%), and CPC 4: 392 (20%), respectively. A total of 232 patients (CPC 5: 12%) died between 30 and 90 days. In 133 patients (7%), 90-day CPC scores improved compared to their 30-day scores. In 260 patients (14%), 90-day CPC scores worsened compared with their 30-day scores. Application of target temperature management was an independent factor for 30- to 90-day neurological improvement (adjusted odds ratio: 1.69, 95% confidence interval: 1.07-2.68).

CONCLUSIONS: In our nationwide registry, 7% of resuscitated patients had improved neurological changes in the 30- to 90-day period; most of the improvements were CPC scores improving from 2 to 1. Target temperature management was an independent factor associated with CPC improvement over the 30- to 90-day period.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Naito H, Nojima T, Yorifuji T, et al. Mid-term (30- to 90-day) neurological changes in out-of-hospital cardiac arrest patients: A nationwide retrospective study (the JAAM-OHCA registry). Am J Emerg Med. 2022. PMID: 35623180. doi:10.1016/j.ajem.2022.05.017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。